50
Participants
Start Date
April 30, 2024
Primary Completion Date
April 30, 2026
Study Completion Date
May 31, 2026
Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor
In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing Friendship Hospital, Beijing
Peking Union Medical College Hospital
OTHER
Peking University Cancer Hospital & Institute
OTHER
Changhai Hospital
OTHER
Beijing Friendship Hospital
OTHER